Ahn IE, Davids MS. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia. Semin Hematol 2024;61(2):109-18. Abstract
Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study. Hemasphere 2023;7(Suppl). Abstract
Al-Sawaf O, Davids MS. Overcoming resistance in chronic lymphocytic leukemia — Maybe less is more? Clin Cancer Res 2024;30(3):471-3. Abstract
Burger J et al. Final analysis of the RESONATE-2 study: Up to 10 years of follow-up of first-line ibrutinib treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA 2024;Abstract P670.
Crombie JL et al. SAVE (Safe Accelerated Venetoclax Escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL. ASCO 2023;Abstract 7512.
Davids MS et al. Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials. Blood Adv 2024;8(13):3345-59. Abstract
Davids MS. Management of Richter transformation. Clin Adv Hematol Oncol 2023;21(8):449-51. Abstract
Eyre TA et al. BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. ASCO 2023;Abstract TPS7583.
Follows G et al. BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma. ASCO 2023;Abstract TPS7582.
Galitzia A et al. Chronic lymphocytic leukemia: Management of adverse events in the era of targeted agents. Cancers (Basel) 2024;16(11):1996. Abstract
Kittai AS et al. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. Blood Adv 2024;8(11):2861-9. Abstract
Kittai AS et al.Anti-CD19 chimeric antigen receptor T-cell therapy for Richter transformation: An international, multicenter, retrospective study. J Clin Oncol 2024;42(17):2071-9. Abstract
Mato AR et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med 2023;389(1):33-44. Abstract
Moreno C et al. First-line fixed-duration ibrutinib plus venetoclax (Ibr + Ven) versus chlorambucil plus obinutuzumab (Clb + O): 55-month follow-up from the GLOW study. ASH 2023;Abstract 634.
Naeem A et al. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv 2023;7(9):1929-43. Abstract
Naeem A et al. Understanding resistance mechanisms and growth kinetics of CLL treated with covalent and non-covalent BTK inhibitors. ASH 2023;Abstract 4623.
Ravikrishnan J et al. LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia. Haematologica 2024;[Online ahead of print]. Abstract
Ryan CE, Davids MS. Practical management of Richter transformation in 2023 and beyond. Am Soc Clin Oncol Educ Book 2023;43. Abstract
Sharman JP et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of ELEVATE-TN. ASH 2023;Abstract 636.
Siddiqi T et al. Lisocabtagene maraleucel (liso-cel) in R/R CLL/SLL: 24-month median follow-up of TRANSCEND CLL 004. ASH 2023;Abstract 330.
Wierda WG et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: Analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol 2024;11(9). Abstract